Stock Quotes & Company News | Reuters.com
Edition:
United States

People: ACADIA Pharmaceuticals Inc (ACAD.O)

ACAD.O on Nasdaq

34.17USD
3:04pm EDT
Change (% chg)

$1.71 (+5.27%)
Prev Close
$32.46
Open
$32.32
Day's High
$34.38
Day's Low
$32.28
Volume
1,348,846
Avg. Vol
3,201,209
52-wk High
$51.99
52-wk Low
$16.64

Moore, Terrence 

Mr. Terrence O. Moore is the Executive Vice President, Chief Commercial Officer of ACADIA Pharmaceuticals Inc., with effect from August 19, 2013. Mr. Moore has more than 25 years of experience as a senior member of sales and marketing teams at several pharmaceutical companies. He has made key contributions to the building of multi-billion dollar brands in the CNS field, including Prozac®, Zyprexa®, Risperdal®, and Effexor XR®. Prior to joining us, Mr. Moore was a Principal of Cooke-Moore Consulting and, before founding that firm, served as Vice President at Transcept Pharmaceuticals, where he was responsible for commercial strategy, business development, and commercial alliance activities. Previously, Mr. Moore served as Vice President, U.S. Head of Neuroscience Marketing at Organon BioSciences and was responsible for the creating and building its Neuroscience Business Unit. He also served as Vice President, U.S. Marketing, Effexor XR®, as well as Vice President, Global Strategy Depression Portfolio at Wyeth Pharmaceuticals. Earlier, Mr. Moore held senior management positions at Johnson & Johnson, where he helped to launch Risperdal® for additional indications in the U.S., and at Eli Lilly, where he held various sales and marketing roles over 14 years, including Zyprexa® Brand Manager. Mr. Moore holds a B.S. in Pharmacy from the University of Florida, a B.A. in Chemistry from the University of South Florida and has completed executive development programs at the Kellogg School of Management and Wharton School of Business.

Basic Compensation

Total Annual Compensation, USD 489,600
Restricted Stock Awards, USD --
Long-Term Incentive Plans, USD --
All Other, USD 724,439
Fiscal Year Total, USD 1,214,040

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --